Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELISS: Belimumab in Primary Sjögren's Syndrome
NCT01160666Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2010
- Primary completion
- Dec 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belimumab in Sjögren's syndrome, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Response Rate (Composite of VAS and Biomarkers) at 28 weeks. Started Mar 2010; status: completed.
02
Drugs
belimumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT01160666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01160666.